EP0261599A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Compositions suitable for human topical application including a growth factor and/or related materials
Assignee: Exovir Inc
•
Filing: 1987-09-18
•
Granted: —
•
Expires: 2007-09-18
Abstract
Abstract Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), tranforming growth factor-alpha (TGFα ), transforming growth factor-beta (TGF-β ), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. These compositions might also usefully contain or have employed in association therewith an adjuvant to aid in the transdermal transport or transfer of the compositions, particularly the active components therein, through or across the skin. Also, these compositions might also have contained therein or employed in association therewith an antiviral agent, such as an antiviral surfactant, for example, an antiviral nonionic surfactant, e.g. nonylphenoxypolyethoxy ethanol and/or human interferon, e.g. alpha-interferon. Additionally, these compositions might contain or have employed in association therewith an antitumor agent, such as tumor necrosis factor (TNF), target cell lysis factor (TCLF) and carcino-breaking factor (CBF). These compositions are useful in the treatment or healing of humans, e.g. in the treatment of viral and/or cancerous skin disorders or lesions and/or to expedite healing.
Inventors
- 👤 Maxwell M. Powell
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 18:01
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K38/17; A61K38/19; A61K38/21; A61P; A61P17/00; A61P35/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
89 words
A composition suitable for topical or subcutaneous application to a human comprising a physiologically acceptable carrier and an effective amount of a material selected from the group consisting of a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α ) transforming growth factor-beta (TGF-β ), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein.
Claim 2
Dependent Claim
89 words
A composition suitable for topical or subcutaneous application to a human comprising a physiologically acceptable carrier and an effective amount of a material selected from the group consisting of a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α ) transforming growth factor-beta (TGF-β ), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein.
Claim 3
Dependent Claim
14 words
A composition in accordance with Claim 1 wherein said carrier includes an antiviral agent.
Claim 4
Dependent Claim
23 words
A composition in accordance with Claim 2 wherein said antiviral agent is a human interferon, such as human alpha-interferon, or an antiviral surfactant.
Claim 5
Dependent Claim
34 words
A composition in accordance with Claim 3 wherein said antiviral surfactant is a nonionic surfactant, such as nonylphenoxypolyethoxy ethanol, p-diisobutylphenoxypolyethoxy ethanol, polyoxyethylene (10) oleyl ether, or onyx-ol, a cationic surfactant, or an anionic surfactant.
Claim 6
Dependent Claim
35 words
A composition in accordance with Claim 1 wherein said carrier includes an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition or material through or across the skin.
Claim 7
Dependent Claim
19 words
A composition in accordance with Claim 5 wherein said adjuvant is dimethylsulfoxide, or a glycol, such as polyethylene glycol.
Claim 8
Dependent Claim
30 words
A composition in accordance with Claim 1 wherein said composition also includes an effective amount of an antitumor agent, such as a lymphotoxin, tumor necrosis factor (TNF) or an interleukin.
Claim 9
Dependent Claim
19 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous carrier, such as an aqueous gel.
Claim 10
Dependent Claim
35 words
A composition in accordance with Claim 1 wherein said carrier is a gel and includes an antiviral surfactant in an amount in the range from about 0.1 to about 20% by weight of said composition.
Claim 11
Dependent Claim
36 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel, said carrier including an effective amount of an antiviral nonionic surfactant and wherein said material is granulocyte macrophage colony stimulating factor (GM-CSF).
Claim 12
Dependent Claim
37 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which includes an effective antiviral amount of human alpha-interferon and wherein said material is granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin.
Claim 13
Dependent Claim
67 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains an effective antiviral amount of human alpha-beta-interferon, an effective amount of an antiviral nonionic surfactant, an effective amount of an adjuvant for assisting in the transdermal transport or transfer of said composition or material where topically applied, and wherein said material is colony stimulating factor (CSF) and epidermal growth factor (EGF).
Claim 14
Dependent Claim
50 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains an adjuvant to assist in the transdermal transport or transfer of said composition or material therein through or across the skin where topically applied and wherein said material is a tissue plasminogen activator (t-PA).
Claim 15
Dependent Claim
43 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains a surfactant and wherein said material is transforming growth factor-alpha (TGF-α ), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), colony stimulating factor (CSF), or a fibronectin.
Claim 16
Dependent Claim
33 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains a surfactant, an antitumor agent and wherein said material is a large external transformation sensitive protein (LETS).
Claim 17
Dependent Claim
74 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains an effective antiviral amount of human alpha-interferon, an effective amount of an antiviral nonionic surfactant, an effective amount of interleukin II and as said material colony stimulating factor (CSF), epidermal growth factor (EGF), transforming growth factor-β (TGF-β ), transforming growth factor- α (TGF- α ), an effective amount of human endothelial cell growth factor (ECGF) and/or a fibronectin.
Claim 18
Dependent Claim
33 words
A composition in accordance with Claim 1 wherein said carrier contains an effective antiviral amount of human alpha-interferon and an effective amount of tumor necrosis factor (TNF), of lymphotoxin, or of interleukin II.
Claim 19
Dependent Claim
33 words
A composition in accordance with Claim 1 wherein said carrier contains an effective antiviral amount of human interferon, an effective amount of tumor necrosis factor (TNF) and an effective amount of a lymphotoxin.
Claim 20
Dependent Claim
41 words
A composition in accordance with Claim 1 wherein said carrier is an aqueous gel which contains an effective antiviral amount of a nonionic surfactant, an effective antiviral amount of human alpha-interferon, and an effective antitumor amount of tumor necrosis factor (TNF).
Claim 21
Dependent Claim
27 words
A composition in accordance with any one of claims 1 to 19 for use in a method of treating viral or cancerous skin disorders in a human.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.